Literature DB >> 15534571

Complications of the intrauterine device in nulliparous and parous women.

H M Veldhuis1, A G Vos, A L M Lagro-Janssen.   

Abstract

OBJECTIVES: The intrauterine device (IUD) is still related to pelvic inflammatory disease (PID), pregnancy, expulsion, perforation and menstrual problems, particularly in nulliparous women. We aimed to study the complications and symptoms of the intrauterine device in general practice, particularly in nulliparous women.
METHODS: We used a retrospective cohort study in four general practices participating in the Nijmegen Continuous Morbidity Registration. Selected women had one or more IUDs inserted between 1981 and 2000. Data on complications, symptoms and removal of the IUD were obtained from the medical records.
RESULTS: 461 women were included, 129 nulliparous and 332 parous women. Users of copper IUDs had a rate of PID of 3.5 per 1000 women-years, rates of (ectopic) pregnancy of 0.6 to 1.1% per year and rates of expulsion of 0 to 1.2% per year. Rates of expulsion for the levonorgestrel-releasing IUDs were 0 to 0.2% per year. Nulliparous women did not show more complications than parous women. Menstrual problems were frequent among users of copper and levonorgestrel-releasing IUDs. One third of the IUDs were removed within the first year after insertion. There was no significant excess of IUD removal among nulliparous women compared with parous women. Main reasons for removal were 'menstrual problems' and 'contraception no longer necessary'.
CONCLUSION: Both copper and levonorgestrel-releasing IUDs are safe and highly effective contraceptives, which can adequately be inserted and monitored by general practitioners in nulliparous and parous women.

Entities:  

Mesh:

Year:  2004        PMID: 15534571     DOI: 10.3109/13814780409044540

Source DB:  PubMed          Journal:  Eur J Gen Pract        ISSN: 1381-4788            Impact factor:   1.904


  9 in total

1.  Failed IUD insertions in community practice: an under-recognized problem?

Authors:  Amna I Dermish; David K Turok; Janet C Jacobson; Marie E S Flores; Molly McFadden; Kathy Burke
Journal:  Contraception       Date:  2012-09-11       Impact factor: 3.375

2.  Discontinuation rates and acceptability during 1 year of using the intrauterine ball (the SCu380A).

Authors:  Ellen Wiebe; James Trussell
Journal:  Contraception       Date:  2015-12-08       Impact factor: 3.375

Review 3.  Levonorgestrel-Releasing Intrauterine System (52 mg) for Idiopathic Heavy Menstrual Bleeding: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2016-11-01

4.  Contraceptive considerations for breastfeeding women within Jewish law.

Authors:  Ilana R Chertok; Deena R Zimmerman
Journal:  Int Breastfeed J       Date:  2007-01-04       Impact factor: 3.461

5.  The Effect of Age, Parity and Body Mass Index on the Efficacy, Safety, Placement and User Satisfaction Associated With Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems: Subgroup Analyses of Data From a Phase III Trial.

Authors:  Kristina Gemzell-Danielsson; Dan Apter; Brian Hauck; Thomas Schmelter; Sarah Rybowski; Kimberly Rosen; Anita Nelson
Journal:  PLoS One       Date:  2015-09-17       Impact factor: 3.240

6.  A Dedicated Postpartum Intrauterine Device Inserter: Pilot Experience and Proof of Concept.

Authors:  Sharad Singh; Vinita Das; Anjoo Agarwal; Rupali Dewan; Pratima Mittal; Renita Bhamrah; Klaira Lerma; Paul D Blumenthal
Journal:  Glob Health Sci Pract       Date:  2016-03-25

7.  Intrauterine contraception in nulliparous women: a prospective survey.

Authors:  Alexandra M Hall; Beth A Kutler
Journal:  J Fam Plann Reprod Health Care       Date:  2015-04-08

8.  The levonorgestrel-releasing intrauterine system: Safety, efficacy, and patient acceptability.

Authors:  Megan N Beatty; Paul D Blumenthal
Journal:  Ther Clin Risk Manag       Date:  2009-08-03       Impact factor: 2.423

Review 9.  A review of barriers and myths preventing the more widespread use of intrauterine contraception in nulliparous women.

Authors:  Kirsten Black; Pamela Lotke; Kai J Buhling; Nikki B Zite
Journal:  Eur J Contracept Reprod Health Care       Date:  2012-07-26       Impact factor: 1.848

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.